#QTTB hashtag - Bluesky

Trade Alerts, Wednesday September 10, 2025 – Crystal Equity Research

6 months ago

Small-cap stock registering bullish MACD crossovers, Wed Sept 10th - #GLXG #SEER #QTTB #OBLG #NVNO #MAXN #LMFA #STRF #MIMI #HUHU #JUNS #AISP #BTBT #CAN - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q32 Bio (NASDAQ: QTTB) has reported its Q2 2025 financial results and provided corporate updates. The company continues to advance its bempikibart development program for alopecia areata (AA), with patient dosing ongoing in both Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial. The company has appointed Dr. Adrien Sipos as Interim Chief Medical Officer and received Fast Track designation for bempikibart.Q32 Bio reported cash and cash equivalents of $54.8 million as of June 30, 2025, extending their runway into 2027. The company's R&D expenses decreased to $5.2 million from $13.4 million year-over-year, while G&A expenses reduced to $4.0 million. Net loss improved to $9.5 million ($0.78 per share) compared to $17.0 million in Q2 2024.

8 months ago

#QTTB Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/QTTB/q32-bio-report...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

8 months ago

Small-cap stocks with improving money flow, Thu Jul 10th - #PXLW #AMTD #KMT #NEGG #LPG #MIST #TRC #HELE #VNCE #CLLS #WTTR #ADTN #QTTB #RMNI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with bullish Moving Average Convergence Divergence Crossovers, Mon May 12th - #LGO #NEO #OCSL #PRPH #QTTB #RBBN #TIL #ULH #VRCA #XFOR #WTF #GRRR #DMLP #CCB #BLMN #ALAR #WSR #WNC #RVLV #HLLY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update Q32 Bio (NASDAQ: QTTB) reported its Q1 2025 financial results and provided key updates on bempikibart, its treatment for alopecia areata (AA). The company achieved several milestones, including Fast Track designation from the FDA and dosing the first patients in both Part B of the SIGNAL-AA Phase 2a trial and the Part A open-label extension. The company presented promising results at the AAD Annual Meeting, showing continued efficacy after treatment cessation.Financial highlights include $65.5 million in cash as of March 31, 2025, providing runway into 2H'26. Q1 2025 saw reduced R&D expenses of $7.1 million (down from $9.8 million in Q1 2024), while G&A expenses remained stable at $5.1 million. The company reported a net loss of $11.0 million ($0.90 per share) compared to net income of $1.0 million in Q1 2024.

10 months ago

#QTTB Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/QTTB/q32-bio-report...

0 0 0 0

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata Q32 Bio has received FDA Fast Track designation for its drug bempikibart (ADX-914) to treat alopecia areata. Bempikibart, a human anti-IL-7Rα antibody that blocks IL-7 and TSLP signaling, is currently in Phase 2 trials through the SIGNAL-AA clinical program. The Fast Track status acknowledges both the serious nature of alopecia areata and the significant unmet medical needs in this field. This designation follows promising clinical activity in Part A of the SIGNAL-AA trial, with dosing now initiated in both Part A's open-label extension and Part B. The Fast Track process aims to speed up drug development and review, potentially offering benefits like more frequent FDA communications, rolling review opportunities, and possible eligibility for Accelerated Approval and Priority Review, helping bring crucial treatments to patients faster.

11 months ago

#QTTB Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

www.stocktitan.net/news/QTTB/q32-bio-announ...

0 0 0 0

Breakthrough: Q32 Bio's Alopecia Treatment Maintains Effects 7 Months After Last Dose New clinical data reveals Q32 Bio's bempikibart demonstrates lasting effects in alopecia patients, with responses continuing 7 months post-treatment. Full analysis inside.

11 months ago

#QTTB Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

www.stocktitan.net/news/QTTB/q32-bio-doses-...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

1 year ago

Small-cap stocks with declining money flow, Wed Mar 12th - #PCRX #THS #ZYXI #WNEB #VANI #TBCH #RGP #QTTB #MRTN #LTRY #KALA #IBCP #HCKT #CTKB #BIRD #AVR #SMP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update Q32 Bio (QTTB) has reported its Q4 2024 financial results and provided corporate updates. The company presented encouraging Phase 2a Part A data for bempikibart in treating alopecia areata (AA) at the 2025 AAD Annual Meeting. The drug demonstrated meaningful clinical activity at week 24 with continued effects after dosing cessation, showing potential as a differentiated AA treatment.Key financial metrics include cash and equivalents of $78.0 million as of December 31, 2024, providing runway into 2H'26. Q4 2024 saw R&D expenses of $10.5 million (up from $8.3M YoY) and G&A expenses of $4.0 million (up from $2.8M YoY). Net loss was $14.2 million ($1.16 per share).The company is advancing two key initiatives: the SIGNAL-AA open-label extension and SIGNAL-AA Part B, both scheduled to dose patients in 1H'25, with Part B topline data expected in 1H'26.

1 year ago

#QTTB Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/QTTB/q32-bio-report...

0 0 0 0

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting Q32 Bio (Nasdaq: QTTB) presented additional results from Part A of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata at the 2025 AAD Meeting. The trial demonstrated encouraging improvements in SALT reduction at week 24 and continued effects after dosing cessation.Key findings include:16% mean SALT score reduction in bempikibart group vs 2% in placebo at week 24 (p=0.045)Continued response improvement through week 36 despite only 24 weeks of treatmentTwo patients showed ongoing responses at week 55, suggesting potential remittive effectsFavorable safety profile with no Grade 3 or higher treatment-related adverse eventsThe company plans to initiate an open-label extension study and SIGNAL-AA Part B in 1H'25, with topline data expected in 1H'26. Part B will include a loading dosing regimen and longer treatment period of 36 weeks with follow-up through week 52.

1 year ago

#QTTB Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

www.stocktitan.net/news/QTTB/q32-bio-presen...

0 0 0 0

Q32 Bio's Strategic Pivot: Alopecia Drug Shows 55-Week Efficacy as Company Streamlines Focus Q32 Bio narrows focus on bempikibart following positive SALT score improvements in alopecia areata trials. Restructuring extends cash runway through 2026.

1 year ago

#QTTB Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

www.stocktitan.net/news/QTTB/q32-bio-announ...

0 0 0 0